News

(RTTNews) - DarioHealth Corp. (DRIO), a digital health company, on Tuesday reported financial results from the second quarter, marking a lower loss as declining revenues were complemented by decreased expenses.

The AI-driven healthcare company provides services relating to health plans, health systems, and lowering the cost of care. The company provides AI-insights, connected devices, and provider-backed clinical care to patients with diabetes, hypertension, weight issues, musculoskeletal and behavioral health needs.

Q2 Financial Highlights:

The company reported a net loss of $7.92 million or $0.85 per share, relatively lower than the net loss of $18.56 million or $3.54 per share in 2025.

This may be attributable to certain discontinued pharmaceutical-related business segments that generated revenue in the previous year.

Net revenue reached $5.18 million, a slight decrease from the $5.37 million recorded a year ago.

Total cost of revenues came to $1.98 million, compared to $2.40 million in the previous year. Operating expenses also dropped 21% on a year-over-year basis.

Cash and cash equivalents as of June 30, 2026, totaled $6.63 million.

Business Updates:

The company added its 5th Fortune 50 client and signed a major health insurer through the Amwell channel partnership.

Another partner, Solera, also expanded Dario coverage to include mental health. Two new product expansions were launched, including Dario Women to help members deal with perimenopause and menopause. Dario Sleep was also initiated for members with sleep apnea. Both programs are expected to generate revenue by the fourth quarter of this year.

DRIO is currently trading at $7.52, down 1.96%.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.